An index comprising three blood biomarkers was strongly associated with a diagnosis of interstitial lung disease (ILD) in systemic sclerosis (SSc) patients, a study in Australia shows. The index was also associated with disease severity, independent of lung function. “Our data supports further investigation of composite biomarker indices as…
News
Analyzing the color of red blood cells could help predict survival outcomes among people with systemic sclerosis (SSc), a study shows. The study, “Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension,” was published in Arthritis…
Systemic sclerosis (SSc) patients with interstitial lung disease (ILD), where the lungs become scarred, are more than three times more likely to be hospitalized due to respiratory failure, according to real-world data collected in the U.S. Other strong risk factors for respiratory failure among hospitalized SSc patients included pneumonia…
People with systemic sclerosis (SSc) who have more severe digestive problems tend to have less diversity in the makeup of bacteria living in their gut, a new study reports. Certain bacterial species, including Lactobacillus — present in commercially available probiotics — are more abundant in SSc patients with more…
Epigenetic changes in immune cells from African American women with systemic sclerosis (SSc) may differ from those in patients in of European ancestry, a study reported. The finding “underscores the importance of research in patients with diverse clinical and sociodemographic characteristics, and of integrating genetic and social factors, to…
More than 30% of people with systemic sclerosis (SSc) are dissatisfied with their lives, and higher levels of dissatisfaction are reported by racial minority groups, a U.S.-based study has found. The spiritual well-being of patients was the strongest contributor to life satisfaction scores. These scores were found to be significantly…
aTyr Pharma plans to test efzofitimod, its lead candidate for treating interstitial lung disease (ILD) associated with systemic sclerosis (SSc), in a Phase 2 clinical study this year in the U.S. The plans come after the U.S. Food and Drug Administration (FDA) cleared an investigational new drug…
Oxygenated hemoglobin may be a new prognosis biomarker for systemic sclerosis (SSc) patients screened for pulmonary hypertension (PH), a study in Germany shows. Low levels of oxygenated hemoglobin (OxyHem), the protein that carries oxygen to body tissues, were significantly associated with worse survival among SSc patients. Also, the…
The levels of three blood proteins — endostatin, basic fibroblast growth factor (bFGF), and platelet-activating factor acetylhydrolase (PAF-AH) beta subunit — may help predict the risk of progression from early to definite systemic sclerosis (SSc), according to a new study. “In particular, endostatin was the protein most strongly associated with…
Talaris Therapeutics plans to continue to recruit people with rapidly progressing diffuse cutaneous systemic sclerosis (dcSSc) at risk for organ failure into FREEDOM-3, a Phase 2 clinical study of its investigational cell therapy FCR001. That’s in spite of the company’s decision to put a stop to its…
Recent Posts
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma
- Limited hand function disrupts daily life for people living with SSc
- Coping with loss is part of living with scleroderma
- CAR T-cell therapy eases SSc symptoms, early trial data show
- Milk-derived particles may offer treatment path for SSc fibrosis